
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-08-05-2015
- Volume 11
- Issue 8
Xcelience Makes Investment in Powdersize
Investment in Powdersize adds particle-size control solutions to Xcelience’s capabilities.
Xcelience, a contract development and manufacturing organization, announced on July 31, 2015 that it has made a structured cash investment in Powdersize, a Pennsylvania-based company specializing in milling, micronization and powder-size classification for the pharmaceutical industry. This investment was made to grow Powdersize’s business and add particle-size control solutions to Xcelience’s capabilities, the company reported in a press statement.
Reducing particle size through micronization is considered the leading technology for increasing the bioavailability of oral dosage forms when the API has solubility issues. Current industry trends increasingly demand micronization of APIs with particle sizes of 1-10µm, Xcelience reports.
Powdersize will continue with expansion plans in a recently added facility, to support the additional business expected with the integration and shared development projects.
Source:
Articles in this issue
over 10 years ago
CDMOs Move Slowly with Expansion Plansover 10 years ago
Accelerating Continuous API Synthesisover 10 years ago
BioOutsource Opens New Facility in Glasgowover 10 years ago
Silicone Rubber Pieces Spur Recall of Teva Productover 10 years ago
Baxter Recalls IV Solution for Container and Particulate Issuesover 10 years ago
Indian API Manufacturer Cited for Recordkeeping Failuresover 10 years ago
FDA Issues Quality Metrics Draft Guidance Document for Commentover 10 years ago
EMA Issues Guideline on Fast Tracking Drugs for Unmet Needsover 10 years ago
SafeBridge Updates Potent API and Drug Manufacturer StatusNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





